Establishing and Externally Validating a Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score-Based Nomogram for Predicting Early Recurrence in BCLC Stage 0/A Hepatocellular Carcinoma Patients After Radical Liver Resection: A Multi-Center Study

References

• Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi:10.3322/caac.21834
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang XP, Feng JK, et al. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. Hepatol Int. 2021;15(3):642–650. doi:10.1007/s12072-021-10174-x
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends. 2021;15(3):138–141. doi:10.5582/bst.2021.01094
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Calderaro J, Petitprez F, Becht E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70(1):58–65. doi:10.1016/j.jhep.2018.09.003
   PubMed Web of Science ®Google Scholar
• Jung SM, Kim JM, Choi GS, et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma. J Gastrointest Surg. 2019;23(2):304–311. doi:10.1007/s11605-018-3927-2
   PubMed Web of Science ®Google Scholar
• Zheng Z, Guan R, Zou Y, et al. Nomogram based on inflammatory biomarkers to predict the recurrence of hepatocellular carcinoma-a multicentre experience. J Inflamm Res. 2022;15:5089–5102. doi:10.2147/JIR.S378099
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Niu K, Zhang W, Lv Q, Zhang Y. How CLSPN could demystify its prognostic value and potential molecular mechanism for hepatocellular carcinoma: a crosstalk study. Comput Biol Med. 2024;172:108260. doi:10.1016/j.compbiomed.2024.108260
   PubMedGoogle Scholar
• Shi Y, Wang Y, Zhang W, et al. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. Front Endocrinol. 2023;14:1153802. doi:10.3389/fendo.2023.1153802
   PubMed Web of Science ®Google Scholar
• Yang C, Wang H, Liu J, et al. Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Front Oncol. 2023;13:1134933. doi:10.3389/fonc.2023.1134933
   PubMed Web of Science ®Google Scholar
• Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6(38):41370–41382. doi:10.18632/oncotarget.5629
   PubMedGoogle Scholar
• Jiang H, Li H, Li A, et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 2016;7(44):72076–72083. doi:10.18632/oncotarget.12271
   PubMedGoogle Scholar
• Peng D, Zhang CJ, Gong YQ, et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 2018;8(1):794. doi:10.1038/s41598-018-19146-y
   PubMedGoogle Scholar
• Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: a propensity matched retrospective cohort study. World J Gastroenterol. 2022;28(27):3476–3487. doi:10.3748/wjg.v28.i27.3476
   PubMed Web of Science ®Google Scholar
• Xu H, Zheng X, Ai J, Yang L. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. Int Immunopharmacol. 2023;114:109496. doi:10.1016/j.intimp.2022.109496
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang D. Prognostic significance of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:821–831. doi:10.2147/JHC.S411521
   PubMed Web of Science ®Google Scholar
• Xia F, Huang Z, Zhang Q, et al. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: what’s the impact? Eur J Surg Oncol. 2023;49(4):771–779. doi:10.1016/j.ejso.2022.11.005
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Wu W, Xu W, Sun W, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology. 2021;61(1):230–239. doi:10.1093/rheumatology/keab305
   PubMed Web of Science ®Google Scholar
• Bluthner E, Bednarsch J, Malinowski M, et al. Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - A retrospective cohort study. Int J Surg. 2019;71:56–65. doi:10.1016/j.ijsu.2019.08.033
   PubMed Web of Science ®Google Scholar
• Wei T, Zhang XF, Xue F, et al. Multi-institutional development and external validation of a nomogram for prediction of extrahepatic recurrence after curative-intent resection for hepatocellular carcinoma. Ann Surg Oncol. 2021;28(12):7624–7633. doi:10.1245/s10434-021-10142-7
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835–1847. doi:10.1016/S0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Beumer BR, Buettner S, Galjart B, et al. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol. 2022;48(3):492–499. doi:10.1016/j.ejso.2021.09.012
   PubMed Web of Science ®Google Scholar
• Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–847. doi:10.1245/s10434-017-6025-x
   PubMed Web of Science ®Google Scholar
• Pang S, Shi Y, Xu D, et al. Screening of hepatocellular carcinoma patients with high risk of early recurrence after radical hepatectomy using a nomogram model based on the gamma-glutamyl transpeptidase-to-albumin ratio. J Gastrointest Surg. 2022;26(8):1–9. doi:10.1007/s11605-022-05326-9
   PubMed Web of Science ®Google Scholar
• Zhang XP, Chen ZH, Zhou TF, et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: a large-scale, multicenter study. Eur J Surg Oncol. 2019;45(9):1644–1651. doi:10.1016/j.ejso.2019.03.043
   PubMed Web of Science ®Google Scholar
• Shi S, Zhao YX, Fan JL, Chang LY, Yu DX. Development and external validation of a nomogram including body composition parameters for predicting early recurrence of hepatocellular carcinoma after hepatectomy. Acad Radiol. 2023;30(12):2940–2953. doi:10.1016/j.acra.2023.05.022
   PubMed Web of Science ®Google Scholar
• Toshida K, Itoh S, Kayashima H, et al. The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child-Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma. Hepatol Res. 2023;53(6):522–530. doi:10.1111/hepr.13885
   PubMed Web of Science ®Google Scholar
• Sargin ZG, Dusunceli I. The effect of HALP Score on the prognosis of gastric adenocarcinoma. J Coll Physicians Surg Pak. 2022;32(9):1154–1159.
   PubMed Web of Science ®Google Scholar
• Feng JF, Wang L, Yang X. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma. Bosn J Basic Med Sci. 2021;21(6):773–781. doi:10.17305/bjbms.2021.5666
   PubMed Web of Science ®Google Scholar
• Hu SJ, Zhao XK, Song X, et al. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma. World J Gastroenterol. 2021;27(4):321–335. doi:10.3748/wjg.v27.i4.321
   PubMed Web of Science ®Google Scholar
• Dagmura H, Daldal E, Okan I. The efficacy of hemoglobin, albumin, lymphocytes, and platelets as a prognostic marker for survival in octogenarians and nonagenarians undergoing colorectal cancer surgery. Cancer Biother Radiopharm. 2022;37(10):955–962. doi:10.1089/cbr.2020.4725
   PubMed Web of Science ®Google Scholar
• Yalav O, Topal U, Unal AG, Eray IC. Prognostic significance of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients undergoing curative resection for colorectal cancer. Ann Ital Chir. 2021;92:283–292.
   PubMedGoogle Scholar
• Zhang D, Zeng H, Pan Y, et al. Liver tumor markers, HALP score, and NLR: simple, cost-effective, easily accessible indexes for predicting prognosis in ICC patients after surgery. J Pers Med. 2022;12(12):2041. doi:10.3390/jpm12122041
   PubMed Web of Science ®Google Scholar
• Toshida K, Itoh S, Nakayama Y, et al. Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment. Int J Clin Oncol. 2023;28(8):1082–1091. doi:10.1007/s10147-023-02358-2
   PubMed Web of Science ®Google Scholar
• Marasco G, Poggioli F, Colecchia A, et al. A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: a multicenter study. Cancers. 2021;13(11):2677. doi:10.3390/cancers13112677
   PubMed Web of Science ®Google Scholar
• Unwith S, Zhao H, Hennah L, Ma D. The potential role of HIF on tumour progression and dissemination. Int J Cancer. 2015;136(11):2491–2503. doi:10.1002/ijc.28889
   PubMed Web of Science ®Google Scholar
• Fu X, Yang Y, Zhang D. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma. Liver Int. 2022;42(3):696–709. doi:10.1111/liv.15115
   PubMed Web of Science ®Google Scholar
• Feng F, Zheng G, Wang Q, et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol. 2018;18(1):148. doi:10.1186/s12876-018-0877-9
   PubMed Web of Science ®Google Scholar
• Itoh S, Yugawa K, Shimokawa M, et al. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open. 2019;3(4):500–508. doi:10.1002/bjs5.50170
   PubMed Web of Science ®Google Scholar
• Wen S, Chen Y, Hu C, et al. Combination of tertiary lymphoid structure and neutrophil-to-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. Front Immunol. 2021;12:788640. doi:10.3389/fimmu.2021.788640
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Hiraoka A, et al. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int. 2020;40(4):968–976. doi:10.1111/liv.14405
   PubMed Web of Science ®Google Scholar
• Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11(3–4):325–351. doi:10.1007/BF01307186
   PubMed Web of Science ®Google Scholar
• Midorikawa Y, Takayama T, Higaki T, et al. High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis. Biosci Trends. 2020;14(5):368–375. doi:10.5582/bst.2020.03230
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu J, Liu Y, et al. Identification reproducible microbiota biomarkers for the diagnosis of cirrhosis and hepatocellular carcinoma. AMB Express. 2023;13(1):35. doi:10.1186/s13568-023-01539-6
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3(4):100316. doi:10.1016/j.jhepr.2021.100316
   PubMedGoogle Scholar
• Jothimani D, Rela M, Kamath PS. Liver cirrhosis and portal hypertension: how to deal with esophageal varices? Med Clin North Am. 2023;107(3):491–504. doi:10.1016/j.mcna.2023.01.002
   PubMedGoogle Scholar
• Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61(2):526–536. doi:10.1002/hep.27431
   PubMed Web of Science ®Google Scholar
• Cortese S, Tellado JM. Impact and outcomes of liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. Cir Cir. 2022;90(5):579–587. doi:10.24875/CIRU.22000041
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez V, Brusadin R, Lopez-Conesa A, et al. Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. Langenbecks Arch Surg. 2021;406(3):763–771. doi:10.1007/s00423-020-02056-x
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang H, Xia Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB. 2019;21(1):1–13. doi:10.1016/j.hpb.2018.07.005
   PubMed Web of Science ®Google Scholar
• Qin L, Li C, Xie F, Wang Z, Wen T. Combination of albumin-bilirubin grade and clinically significant portal hypertension predicts the prognosis of patients with hepatocellular carcinoma after liver resection. Biosci Trends. 2021;15(1):41–49. doi:10.5582/bst.2021.01064
   PubMed Web of Science ®Google Scholar
• Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638. doi:10.3389/fimmu.2022.1019638
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi:10.1245/s10434-019-07227-9
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503. doi:10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10–24. doi:10.1097/00000658-200007000-00003
   PubMed Web of Science ®Google Scholar
• Guo B, Chen Q, Liu Z, Chen X, Zhu P. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Front Oncol. 2023;13:1098958. doi:10.3389/fonc.2023.1098958
   PubMed Web of Science ®Google Scholar